-
MARTIN REISER New on this filingPreviously held: Policy Director, Republican Whip Steve Scalise, professional staff House Ways and Means Committee, Chief of Staff, Rep. Dan Miller, Budget Associate, House Budget Committee
-
MICHAELEEN EARLE CROWELL New on this filingPreviously held: Leg Director, Rep. Denise Majette; Leg Director, Rep. John Lewis; Chief of Staff, US Sen. Bernie Sanders
-
KEVIN CASEY New on this filingPreviously held: Senior Pol Dir, Dem Caucus; Counselor, Leg. Dir, Leg. Asst, Rep. Joseph Crowley; Staff Asst, Leg. Correspondent, Rep. Bob Weygand
-
MALLOY MCDANIEL New on this filingPreviously held: Policy Advisor, Senate Minority Leader Mitch McConnell; Whip Liaison, Senate Majority Whip Mitch McConnell; Floor Assistant, Senate Majority Leader Trent Lott; Cloakroom Assistant, Office of the Republican Secretary
-
CHRISTOPHER BUKI New on this filingPreviously held: Staff Assistant/Legislative Correspondent, Representative John Culberson; Legislative Assistant/Senior Legislative Assistant, Representative Bill Shuster; Legislative Director/Deputy Chief of Staff, Representative David McKinley
-
OLIVIA KURTZ New on this filingPreviously held: Chief of Staff, Leg Director, Dep Leg Director, Sr Leg Asst, US Sen Susan Collins; Dep Staff Dir, Sen Special Comm on Aging; Leg Director, Sr Leg Asst, Leg Asst, Exec Asst, Rep Mike Castle
Issues related to compounding and counterfeit drugs; drug pricing and implementation of the Inflation Reduction Act; coverage of anti-obesity medications; pharamcy benefit management reforms; Most Favored Nation drug pricing; tariffs; importation of counterfeit drugs.
Issues related to compounding and counterfeit drugs; drug pricing and implementation of the Inflation Reduction Act; coverage of anti-obesity medications; pharamcy benefit management reforms; Most Favored Nation drug pricing; tariffs; importation of counterfeit drugs.
Issues related to compounding and counterfeit drugs; drug pricing and implementation of the Inflation Reduction Act; coverage of anti-obesity medications; pharamcy benefit management reforms; Most Favored Nation drug pricing; tariffs; importation of counterfeit drugs.